Compounds that inhibit Hsp90 protein-protein interactions with IAP proteins
Patent 7342093 Issued on March 11, 2008. Estimated Expiration Date: July 22, 2025. Estimated Expiration Date is calculated based on simple USPTO term provisions. It does not account for terminal disclaimers, term adjustments, failure to pay maintenance fees, or other factors which might affect the term of a patent.
530/324, 25 or more amino acid residues in defined sequence530/325, 24 amino acid residues in defined sequence530/326, 15 to 23 amino acid residues in defined sequence530/327, 11 to 14 amino acid residues in defined sequence530/328, 8 to 10 amino acid residues in defined sequence530/329, 6 to 7 amino acid residues in defined sequence514/2, Peptide containing (e.g., protein, peptones, fibrinogen, etc.) DOAI514/44, Polynucleotide (e.g., RNA, DNA, etc.)435/226, Derived from animal tissue (e.g., rennin, etc.)435/6Involving nucleic acid
Disclosed herein are compounds that inhibit Hsp90 interactions with IAP proteins, such as Survivin, XIAP, cIAP1, or cIAP2, and methods for identifying and using such compounds.
Claims
What is claimed is:
1. An isolated Survivin protein fragment that consists of a peptide selected from the group consisting of SEQ ID NOS: 3-6, 8-9, 19, 20, 22, and 24.
2. An isolated compound that comprises no more than fifty contiguous amino acid residues of the Survivin protein, wherein the compound comprises a Survivin protein fragment selected from the group consisting of SEQ ID NOS: 3-6, 8-9, 19, 20, 22,and 24; and wherein said peptide fragment is bound at either the N- or C-terminus to the internalization peptide sequence of an internalization sequence containing protein selected from the group consisting of: Tat, Antennapedia, VP22, Pep-1, andtransportan.
Other References
Zou et al., “An APAF-1•cytochrome c multimeric complex is a functional apoptosome that activates procaspase-9,” J. Biol. Chem., 274:11549-56 (1999).
Stebbins et al., “Crystal structure of an Hsp90-geldanamycin complex: targeting of a protein chaperone by an antitumor agent,” Cell, 89:239-250 (1997).
Roy et al., “The gene for neuronal apoptosis inhibitory protein is partially deleted in individuals with spinal muscular atrophy,” Cell, 80:167-78 (1995).
Rothe et al., “The TNFR2-TRAF signaling complex contains two novel proteins related to baculoviral inhibitor of apoptosis proteins,” Cell, 83:1243-52 (1995).
Plescia et al., “Rational design of shepherdin, a novel anticancer agent,” Cancer Cell, 7:457-468 (2005).
O'Connor et al., “Regulation of apoptosis at cell division by p34cdc2 phosphorylation of survivin,” Proc. Natl. Acad. Sci. USA, 97:13103-7 (2000).
Morris et al., “A peptide carrier for the delivery of biologically active proteins into mammalian cells,” Nature Biotech., 19:1173-1176 (2001).
Lundberg and Johansson, “Positively charged DNA-binding proteins cause apparent cell membrane translocation,” Biochem. Biophys. Res. Comm., 291:367-371 (2002).
Liston et al., “Suppression of apoptosis in mammalian cells by NAIP and a related family of IAP genes,” Nature 379:349-53 (1996).
Li et al., “Pleiotropic cell-division defects and apoptosis induced by interference with survivin funtion,” Nat. Cell. Biol., 1:461-6 (1999).
Li et al., “Control of apoptosis and mitotic spindle checkpoint by survivin,” Nature 396:580-584 (1998).
Kelemen et al., “Selective in vivo inhibition of mitogen-activated protein kinase activation using cell-permeable peptides,” J. Biol. Chem., 277:8741-8748 (2002).
Hom et al., “Design and synthesis of statine-based cell-permeable peptidomimetic inhibitors of human β-secretase,” J. Med. Chem., 46:1799-1802 (2003).
Hengartner, “Cell death and aging, molecular mechanisms of,” Molecular Biology and Biotechnology, A Comprehensive Desk Reference, 1995.
Hay et al., “Drosophila homologs of baculovirus inhibitor of apoptosis proteins function to block cell death,” Cell 83:1253-62 (1995).
Grossman et al., “Expression of the apoptosis inhibitor, survivin, in nonmelanoma skin cancer and gene targeting in a keratinocyte cell line,” Lab. Invest., 79:1121-6 (1999).
Grossman et al., “Expression and targeting of the apoptosis inhibitor, survivin, in human melanoma,” J. Invest. Dermatol., 113:1076-81 (1999).
Fortugno et al., “Survivin exists in immunochemically distinct subcellular pools and is involved in spindle microtubule function,” J. Cell Sci., 115:575-585 (2002).
Fortugno et al., “Regulation of survivin function by Hsp90,” Proc. Natl. Acad. Sci. USA, 100:13791-796 (2003).
Duckett et al., “A conserved family of cellular genes related to the baculovirus iap gene and encoding apoptosis inhibitors,” EMBO J., 15:2685-94 (1996).
Duchosal et al., “In vivo immunosuppression by targeting a novel protease receptor,” Nature 380:352-6 (1996).
Deveraux and Reed, “IAP family proteins—suppressors of apoptosis”, Genes Dev., 13:239-252 (1999).
Clem et al., “Anti-apoptotic genes of baculoviruses,” Death and Differentiation, 3:9-16 (1996).
Clem and Miller, “Control of programmed cell death by the baculovirus genes p35 and iap,” Mol. Cell. Biol., 14:5212-22 (1994).
Chen et al., “Selective killing of transformed cells by cyclin/cyclin-dependent kinase 2 antagonists,” Proc. Natl. Acad. Sci. USA, 96:4325-4329 (1999).
Bonny et al., “Cell-permeable peptide inhibitors of JNK: novel blockers of β-cell death,” Diabetes, 50:77-82 (2001).
Birnhaum et al. , “An apoptosis-inhibiting gene from a nuclear polyhedrosis virus encoding a polypeptide with Cys/His sequence motifs,” J. Virol., 68:2521-8 (1994).
Basso et al., “Ansamycin antibiotics inhibit Akt activation and cyclin D expression in breast cancer cells that overexpress HER2,” Oncogene, 21:1159-1166 (2002).
Ambrosini et al., “A novel anti-apoptosis gene, survivin, expressed in cancer and lymphoma,” Nat. Med., 3:917-921 (1997).
Ambrosini and Altieri, “Molecular dissection of effector cell protease receptor-1 recognition of factor Xa: assignment of critical residues involved in antibody reactivity and ligand binding,” J. Biol. Chem., 271:1243-8 (1996).
Altieri, “Xa receptor EPR-1,” FASEB J. 9:860-5 (1995).
Altieri, “Splicing of effector cell protease receptor-1 mRNA is modulated by an unusual retained intron,” Biochem., 33:13848-55 (1994).
Altieri, “Molecular cloning of effector cell protease receptor-1, a novel cell surface receptor for the protease factor Xa,” J. Biol. Chem., 269:3139-42 (1994).
Adida et al., “Developmentally regulated expression of the novel cancer anti-apoptosis gene survivin in human and mouse differentiation,” Am. J. Pathol., 152:43-9 (1998).
July 22, 2025. Estimated Expiration Date is calculated based on simple USPTO term provisions. It does not account for terminal disclaimers, term adjustments, failure to pay maintenance fees, or other factors which might affect the term of a patent.
